Summary A common characteristic of cancer cells is unrestrained cell division. This may be caused by mutational changes in genes coding for components of cell cycle-controlling networks. Alterations in genes involved in G, checkpoint control have been registered in many human tumours, and investigations from several laboratories show that such alterations, taken together, are the most frequent changes detected in cancer cells. The present paper describes mutational analysis by polymerase chain reaction-single-strand conformation polymorphism (PCR/SSCP) and nucleotide sequence analysis of the genes coding for the p15, p53 and N-ras proteins in 26 metastases from 25 melanoma patients. The registered mutation frequencies add together with previously registered mutations in p16 in the same patient samples to a substantial total frequency of 44% of patients with mutation in at least one of the investigated genes. These results show the occurrence of heterogeneous defects among components of the cell cycle controlling machinery in a human melanoma tumour sample collection and demonstrate that the total frequency of detected alterations increases with the number of cell cycle controlling genes included in the screening panel.
The p16 protein, product of the CDKN2A (MTS-J) suppressor gene, is a specific inhibitor of the CDK4 and CDK6 interactions with cyclin D (Serrano et al., 1993; Grana and Reddy, 1995) . Mutational alteration or inactivation of p16 may result in disturbance of the cell cycle G1 checkpoint control and deregulation of cell growth (Clurman and Roberts, 1995; Cordon-Cardo, 1995) . Linkage studies among members of melanoma/dysplastic naevus syndrome (DNS) families have pointed out the chromosome 9p2i region as the likely site for at least one tumour-suppressor gene locus responsible for inherited melanoma predisposition (CannonAlbright et al., 1992; Goldstein et al., 1994) . The CDKN2 gene has recently been mapped to this region (Kamb et al., 1994a; Nobori et al., 1994) and germline mutations in CDKN2 segregating with melanoma have been registered in families from the United States, Holland and Sweden (Hussussian et al., 1994; Kamb et al., 1994b; Platz et al., 1995a) , indicating that this gene may be involved in melanoma heredity in at least one subgroup of melanomaprone families.
A structurally highly related protein, p15, has recently been identified (Hannon and Beach, 1994) . The gene CDKN2B (MTS-2) encoding p15 is located on the short arm of human chromosome 9 adjacent to the p16 gene and may be a second suppressor gene critical for the development of human tumours. Functional studies of binding and inhibitory capability of cyclin-dependent kinases were carried out for both p15 and p16. They revealed specific binding to CDK4 and CDK6 as well as inhibition of the cyclin D-CDK4 and cyclin D-CDK6 enzyme complexes. Both proteins therefore play a functional role in the control of the cell cycle G1 restriction point, and alterations of the CDKN2B gene may thus take part in the molecular pathogenesis of both hereditary and sporadic melanoma. The p53 protein, product of a third tumour-suppressor gene, binds to the promoter of the WAF I gene and activates its transcription, leading to the accumulation of its protein product p21 and to inhibition of CDK-cyclin D interactions and G, cell cycle arrest (Levine et al., 1991; Harris and Holstein, 1992; El Diery et al., 1993; Hunter and Pines, 1994) . Thus, mutational alterations of p53 constitute an additional genetic defect leading to cell cycle deregulation and a tumorigenic phenotype (Soussi et al., 1994 ).
The ras genes, H-ras, Ki-ras 2 and N-ras, encode 21 kDa proteins belonging to a large family of GTP-binding proteins that play a key role in signal transduction leading from cellsurface receptors to the interior of the cell, thereby forming a functional part of proliferation control. Controlled proliferation, however, is disrupted by mutational alterations of the ras genes (Barbacid, 1978) . The ras genes can become activated via point mutations in codon 12, 13 or 61. The mutated forms act as oncogenes and have commonly been detected in many types of tumours (Bos, 1989) . In addition, ras alterations may affect cell cycle control. Recently published data point to an effect of activated H-ras p21 leading to overexpression of cyclin Dl (Filmus et al., 1994) . Altered N-ras genes, predominantly with mutations in codon 61 and/or altered N-ras gene expression levels have been registered in human melanomas (Albino et al., 1989; Van't Veer et al., 1989; Ball et al., 1994; Platz et al., 1994 Platz et al., , 1995b .
Mutated variants of the p53 and CDKN2A genes are commonly found in tumour cell lines and have also been detected in a number of human tumour tissues (Holstein et al., 1991; Caldas et al., 1994; Okamoto et al., 1994; Mori et al., 1994; Zhou et al., 1994) . Mutational analyses of both p53 and CDKN2A in tumour samples from sporadic human malignant melanoma have been carried out by several investigators, but conflicting results have been obtained (Volkenandt et al., 1991; Castresana et al., 1993; Florenes et al., 1994; Ohta et al., 1994; Gruis et al., 1995; Platz et al., 1996) . No report on mutational alteration of the p15 gene CDKN2B in sporadic human malignant melanoma has yet been published.
We have recently registered the presence of somatic mutations in the CDKN2A gene in melanoma metastases from 3/25 (12%) of patients with sporadic cutaneous malignant melanoma (Platz et al., 1996) . The present report describes the mutational analysis of the same patient samples for CDKN2B exons 1 and 2, for p53 exons 4-9 and for N-ras exon 2, by polymerase chain reaction-single-strand-conformation polymorphism (PCR/SSCP) and their final characterisation by nucleotide sequence analysis. In addition, p53 was studied by immunohistochemical analysis using the mouse monoclonal antibody DO-1. human wild-type and mutant p53 protein (Oncogene Science, Manhasset, NY, USA) was used on 4 gum sections of formalin-fixed tumour tissue as described earlier (Platz et al., 1995b) . The sections were pretreated with microwaves in a Microwave Tender CookerR (Nordic Ware, Minneapolis, MN, USA) placed in a household microwave oven. The treatment was for 15 min at maximum power and for an additional 10 min at 65% power setting. The lower limit for p53 immunopositivity was arbitrarily set at 1% of positive cells.
Polymerase chain reaction (PCR) and single strand conformation polymorphism analysis (SSCP) Amplification of CDKN2A exon regions and their SSCP analysis has been reported earlier (Platz et al., 1996) . The CDKN2B exon 1 and 2 regions were separately amplified. Exon 1 was amplified as a 310 bp fragment using the primers p151S and p1SlA and cleaved with BamHI into two fragments of 132 bp and 178 bp. Exon 2 was amplified either with the primers p152S and p152A resulting in a fragment of 429 bp which was cleaved with SmaI into two fragments of 195 bp and 234 bp, or with the primers 89F and 5OR (Kamb et al., 1994a) resulting in a fragment of 530 bp which was cleaved into fragments of 208 and -320 bp. The PCR programmes were 30 cycles at 94°C for 30 s, 60°C for 30 s, 90°C for 30 s. SSCP runs were always carried out with both the intact and the cleaved PCR fragments.
The genomic regions containing the p53 exons 4 to 9 were separately amplified using primer combinations resulting in fragment sizes from 171 to 325 bp, suitable for efficient SSCP (Naito et al., 1992) . The genomic region including exon 5 and exon 6 was also amplified as one single fragment, including the intervening sequence, by the primer combination DI/E2, exon 5-6, or as two overlapping segments using the primer combinations Dl/D2, exon 5-6, or E1/E2, exon 5-6 (Kishimoto et al., 1992) . The N-ras exon 2 region was amplified as a 118 bp fragment using the primer pair N-ras 5'/N2b, as previously described (Platz et al., 1994) . All primer sequences are summarised in Table I ---------------------- In one sample a p53 exon 4 band shift was observed and in six samples band shifts for the exon 5-6 region were seen. In two more samples N-ras exon 2 band shifts were detected (Figure 1 ).
Nucleotide sequence analysis Nucleotide sequence changes were with one exception exclusively detected in samples that also had SSCP band shifts. The remaining samples had the wild-type sequence, the sole exception being from patient AI, who had a point mutation in CDKN2B but no clear bandshift in SSCP. The registered mutations are summarised in Table III and Otsuki et al., 1995) in the noncoding sequence 5' to exon 2 of CDKN2B (at nucleotide position 74) was found by both SSCP and nucleotide sequence analysis in metastases from five (20%) of the patients. Patients BT, EE and GL with p53 mutations in their metastases showed no corresponding wild-type allele. Two metastases of patient MP and a metastasis of patient TN had silent mutations in the Arg-213 codon of p53. The wild-type N-ras allele was not detectable in the metastasis of patient JA who had a mutation in N-ras exon 2, whereas both a mutant and the wild-type Nras allele was registered in the metastasis from patient WN.
Discussion
Disturbances of cell cycle control may result in unregulated cell growth and consequently in tumour formation. The cell cycle is governed by a complex network of interacting proteins which at this stage is partially understood (Hartwell and Kastan, 1994) . Several major checkpoints have been identified. One of them, the GI restriction point, is the site at which the decision for cell division is taken. Defects in any of the participating proteins may lead to genomic instability and contribute to the development of malignancy. Mutations and altered expression patterns of genes coding for components of cell cycle regulation have been reported in a variety of human neoplasms (CordonCardo, 1995) .
The mutational analysis of metastases from 25 patients with sporadic melanomas in the present investigation shows the occurrence of mutated forms of the CDKN2B, p53 and N-ras genes. The same samples had previously been analysed for CDKN2A and mutant alleles found (Platz et al., 1996) .
The registered alterations comprise point mutations exclusively. No indication of small deletions could be recognised, since all samples efficiently yielded fragments of expected sizes by PCR. Histological examination of the tumour tissue pieces revealed the presence of highly homogeneous tumour cell populations. There was no sign of homozygous deletions involving the investigated gene regions within the limits of the employed PCR method (Platz et al., 1996) . The presence of subclones with gene losses may, however, have escaped detection. Altogether, the obtained results show that 10 of 25 patients had metastases with single mutational changes in one of the four investigated genes. One patient had a metastasis which contained both a CDKN2A and a p53 mutation.
The DO-1 monoclonal p53-specific antibody selectively recognised the two p53 missense mutants in the metastases from patients BT and GL but, as expected, did not recognise the truncated protein product in the metastasis The combined results of studies concerning mutations of cell cycle-related proteins in tumours and tumour cell lines reported by many investigators show that such alterations are the most common genetic changes in tumour cells (Clurman and Roberts, 1995) . The present mutation screening, while reporting relatively low frequencies of changes for any of the four genes alone, indicates a substantial total frequency of 44% (48% if two silent p53 mutations are counted) of patients with mutations and may hypothetically approach the 100% level when additional genes with functional connection to cell cycle control are included in forthcoming studies.
